Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
暂无分享,去创建一个
F. Holmes | J. O’Shaughnessy | J. Pippen | H. Muss | R. Mennel | J. Blum | S. Vukelja | M. Savin | D. Richards | Joyce O'Shaughnessy | Stephen Jones | Frankie Ann Holmes | Joanne L Blum | Svetislava J Vukelja | Kristi J McIntyre | John E Pippen | James H Bordelon | Robert L Kirby | John Sandbach | William J Hyman | Donald A Richards | Robert G Mennel | Kristi A Boehm | Wally G Meyer | Lina Asmar | Daniel Mackey | Stefan Riedel | Hyman Muss | Michael A Savin | L. Asmar | J. Sandbach | Stephen N. Jones | K. McIntyre | W. Hyman | K. Boehm | J. H. Bordelon | R. Kirby | W. Meyer | Stefan Riedel | D. Mackey
[1] J. Bryant,et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Berry,et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] F. Holmes,et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[5] J. Goodwin,et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Ja. Evidence-based clinical practice guidelines. , 2000, Seminars in perioperative nursing.
[7] F. O'Malley,et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] John R. Mackey,et al. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .
[9] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[10] C. Criscitiello,et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Hortobagyi,et al. Acute myeloid leukemia (AML) in older women after adjuvant breast cancer therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Larry Norton,et al. HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.
[13] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[14] G. Hortobagyi,et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[16] T. Delozier,et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Cohen,et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. , 2005, JAMA.
[19] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Namer,et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] G. Hortobagyi,et al. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Donald A. Berry,et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .
[23] M. Sormani,et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. , 2008, Journal of the National Cancer Institute.